Aeovian Pharmaceuticals is excited to announce a milestone funding achievement with a successful raise of $50,000,000 to propel its innovative research and development efforts. As a clinical-stage biopharmaceutical company committed to addressing complex, life-altering diseases, Aeovian is at the forefront of developing targeted, highly selective small molecules designed to restore cellular metabolic quality control. This crucial process plays a significant role in mitigating the dysregulated growth and hyperactive signaling observed in certain rare genetic and age-related disorders. The newly secured funds will primarily support ongoing research and clinical trials, especially for the company鈥檚 lead development candidate, AV078. AV078 is a first-in-class, CNS-penetrant, selective mTORC1 inhibitor currently under evaluation in a Phase 1 trial for the treatment of TSC refractory epilepsy鈥攁 condition caused by the rare genetic disorder TSC, characterized by the hyperactive signaling of mTORC1.
In addition to accelerating the clinical advancement of AV078, the funding will enable Aeovian to expand its robust pipeline. The investment will also bolster efforts in optimizing its proprietary library of small molecules, including potent inhibitors of mTORC1 and CD38, which hold significant promise in precisely targeting the biological mechanisms underlying multiple rare and age-related diseases. This new capital infusion underscores the confidence of investors in Aeovian鈥檚 strategic vision and its capacity to make transformative contributions to therapeutic innovation. With an unwavering focus on improving patient outcomes, Aeovian Pharmaceuticals is poised to redefine treatment paradigms and bring hope to those affected by challenging diseases worldwide.
